iberdomide (CC-220) / BMS - LARVOL DELTA

Interim analysis of efficacy and safety for ALLG MM25 (Viber-M): A phase I b/II study of venetoclax, iberdomide and dexamethasone for patients in first or second relapse of multiple myeloma with t(11; 14) (ASH 2025) - "Given the high attrition rates in patient numbers at each relapse,prioritising effective treatments early in the disease course is vital.In the era of lenalidomide (Len)-based induction and maintenance, there is need for a Len-free regimenat relapse. Iberdomide (Iber) is a potent oral cereblon E3 ligase modulator (CELMoD)...G3/4 TEAEs were reported in 11 patients (55%), with neutropenia being the most common(45%); 12 patients (60%) required filgrastim support...As of data cutoff, 44 of 50 patients have been enrolled. The planned interim analysis was conducted forthe first 20 patients (median age 65 years; range 41-83) following completion of three treatment cycles.Of these, 12 (60%) underwent planned dose escalation over three cycles, and 8 (40%) over two cycles. Themajority (75%) had one prior LOT."

Clinical • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Lymphoma • Multiple Myeloma • Neutropenia • Targeted Protein Degradation • Thrombocytopenia • CRBN

An immune-therapeutic salvage strategy for 'functional' high-risk (FHR) multiple myeloma (MM) incorporating iberdomide, isatuximab, and dexamethasone – the IBIS study amarc 20-01. (ASH 2025) - P2 | "Of 50 pts: 28%, 32%, 16%, 12% with 0, 1, 2 or 3 high-risk chromosomal abnormalitiesrespectively; 34% fulfilling IMS2025 high-risk criteria, 54% standard-risk and 12% in whom diagnosticCG/FISH were omitted, 83% received PI-IMID 1L (76% VRd, 3% VRd+chemotherapy, 7% VRd+Selinexor),10% bortezomib-cyclophosphamide-dexamethasone (VCD), 7% lenalidomide-dexamethasone (Rd), 24%ASCT; 10% 1REF to 1L and 90% relapsed after initial response to 1L, of these 72% had ³PR to 1L. In this second planned interim analysis, IB-IS-DEX was well-tolerated, achieved early diseasecontrol and demonstrated promising efficacy in FHR MM. Preliminary ctDNA genomic analyses highlight asubstantial burden of adverse biology, with frequent del(17p), MYC copy number gains, and high cTFamong pts with PD. Updates on survival will be presented at the conference."

CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Infectious Disease • Insomnia • Multiple Myeloma • Neutropenia • Respiratory Diseases • Septic Shock • Sleep Disorder • Squamous Cell Carcinoma

Maintenance Therapy with Iberdomide Following Autologous Hematopoietic Cell Transplantation in Lenalidomide-Exposed Multiple Myeloma Patients (TCT-ASTCT-CIBMTR 2026) - P2 | "Iberdomide (iber), a CELMoD with higher potency than lenalidomide or pomalidomide, may deepen responses and extend disease control post-AHCT. Interpret clinical efficacy and safety outcomes from a phase II trial of iberdomide maintenance in high-risk multiple myeloma 3 . Evaluate how post-salvage maintenance approaches like iberdomide can extend disease control, inform clinical decision making, and shape future therapeutic sequencing in the modern MM treatment landscape."

Clinical • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Transplantation

Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial (ASH 2025) - P1/2 | "Introduction: Lenalidomide (LEN) plus daratumumab (DARA) and dexamethasone (DEX) is a standard-of-care treatment for transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM). Despite the observed numerical differences in ORR and CR between RI subgroups, logisticregression analyses showed no correlation between baseline CrCl and key efficacy and safety endpoints,suggesting that RI does not impact clinical outcomes in pts with TNE NDMM treated with IberDd, and thatIBER dose modifications are not required for pts with mild to moderate RI. These data are consistent withprevious observations in pts with RRMM receiving IBER+DEX."

Clinical • Febrile Neutropenia • Infectious Disease • Lymphoma • Multiple Myeloma • Neutropenia • Plasmacytoma • Renal Disease • CRBN • IKZF1

Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial (ASH 2025) - P2 | "All pts received a PI/IMiD-containing induction regimen, which also includeddaratumumab in 53% of pts. These data support the investigation of iberdomide versus lenalidomide maintenance inthe ongoing phase 3 registrational EXCALIBER Maintenance trial. The dose of 0.75 mg iberdomide waschosen as the recommended maintenance dose for further evaluation, based on comparable efficacywith superior tolerability, compared to higher doses of iberdomide."

Clinical • P2 data • Cardiovascular • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia • Transplantation • Venous Thromboembolism

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy Results (ASH 2025) - P1, P3 | "GOLCA drivesthe closed, active conformation of cereblon to induce rapid and deep degradation of Ikaros and Aiolos,leading to direct cell killing (agnostic of cell of origin [COO]) and immunomodulatory activity.CC-220-DLBCL-001 (NCT04884035) is an ongoing Phase 1b, open-label, multicenter trial to assess safetyand preliminary efficacy of GOLCA+R-CHOP in previously untreated a-BCL. GOLCA+R-CHOP demonstrated a predictable and manageablesafety profile with low rates of non-hematologic AEs; addition of GOLCA to R-CHOP did not compromiseSOC delivery. These data continue to show that GOLCA 0.4mg, when added to SOC Tx, has a potential tocure more previously untreated pts with HR LBCL and support the ongoing Phase 3 trial, GOLSEEK-1, inthis population (NCT06356129)."

Clinical • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Gastrointestinal Disorder • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • CRBN • IKZF1

A phase 2 trial of iberdomide, carfilzomib, daratumumab and dexamethasone quadruplet therapy for relapsed/refractory multiple myeloma: The rekindle study (ASH 2025) - P2 | "In this context, Iberdomide is a potent cereblon E3 ligase modulator (CELMoD)with demonstrated activity in IMiD-resistant disease (Lonial et al., Lancet Haematology. This quadruplet reinduction strategy adds another treatment alternative in the early relapsesetting (i.e., following lenalidomide resistance; 1-3 prior lines) where parenteral (SC or IV) T-cellredirecting therapies are gaining increased prominence. IberKDd is safe with a manageable toxicityprofile, and it affords the opportunity for de-escalation to oral monotherapy; decreasing the burden ofcontinuous parenteral therapy which is common in this setting of MM."

P2 data • Cardiovascular • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukopenia • Multiple Myeloma • Myocardial Infarction • Neutropenia • Respiratory Diseases • Targeted Protein Degradation • Thrombocytopenia • CRBN

All-oral triplet iberdomide, ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D. (ASCO 2024) - P2 | "Background: The triplet combination daratumumab, lenalidomide and dexamethasone (DRd) and bortezomib, lenalidomide and dexamethasone (VRd) are to date the standard of care for patients with transplant ineligible (TI) newly diagnosed multiple myeloma (MM)...Iberdomide is a novel oral cereblon E3 ligase modulator (CELMoD) that demonstrated promising activity in MM patients refractory to lenalidomide/pomalidomide... The oral tripletiberdomide, ixazomib and dexamethasone demonstrated a favorable efficacy / safety profile in elderly MM patients at first relapse, including in patients with lenalidomide and daratumumab refractory disease."

Clinical • P2 data • Dermatology • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Oncology • Pain • Targeted Protein Degradation • Thrombocytopenia • CRBN

Carfilzomib, iberdomide, and dexamethasone (KID) in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): Updated results from phase 1/2 study. (ASCO 2025) - P1/2 | "Iberdomide, a cereblon modulator, enhances immune stimulatory activity in vitro compared to thalidomide analogs... Induction therapy with KID appears safe and effective leading to deep responses and adequate stem cell collection despite short tx duration and 42% harboring high-risk cytogenetics. Long-term follow-up is needed to determine durability of response. Correlative studies are underway to evaluate immune phenotype and microbiome changes pre/post-tx."

Clinical • P1/2 data • Anemia • Dermatology • Hematological Malignancies • Multiple Myeloma • Neutropenia • Oncology • Pruritus • Thrombocytopenia • Transplantation • CRBN • TP53

Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial (ASH 2025) - P1, P2 | "The study continuesenrolling and will explore ELRA + IBER in a larger group of pts with RRMM. Results from a longer follow-up will be presented."

Clinical • Combination therapy • P1 data • Anorexia • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia

Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial. (PubMed, Lancet Haematol) - P2 | "IberCd is an all-oral and active combination for patients with relapsed and refractory multiple myeloma that showed clinically meaningful activity. This regimen offers a valuable treatment option for patients who have received two to four previous lines of therapy and compares favourably with other available treatments."

Journal • P2 data • Cardiovascular • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Novel Coronavirus Disease • Oncology • Targeted Protein Degradation • Venous Thromboembolism • CRBN

Targeting Ikaros and Aiolos: Next-Generation Cereblon E3 Ligase Modulators in MM. (PubMed, Eur J Haematol) - "With frontline therapeutic strategies increasingly employing quadruplet induction regimens and prolonged lenalidomide maintenance, resistance to traditional IMiDs has become more prevalent, creating an urgent need for next-generation cereblon E3 ligase modulators (CELMoDs) capable of overcoming IMiD refractoriness and enhancing the immunologic microenvironment. Iberdomide (CC-220) and mezigdomide (CC-92480) are rationally engineered CELMoDs designed to achieve deeper degradation of Ikaros (IKZF1) and Aiolos (IKZF3), restore cereblon-mediated activity, and potentiate immune effector responses...We examine how their pharmacodynamic properties differ from classical IMiDs, their relevance in triple-class and penta-refractory MM, and their integration into emerging combination strategies with monoclonal antibodies and T-cell-redirecting immunotherapies. Special emphasis is placed on ongoing and future trials that may refine their therapeutic positioning, alongside a critical..."

Journal • Review • Hematological Malignancies • Immunology • Multiple Myeloma • Oncology • Targeted Protein Degradation • CRBN • IKZF1 • IKZF3

MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial. (ASCO 2025) - P3 | "Funded by No funding sources reported Clinical Trial Registration Number: NCT04934475 Background: The phase III IFM2020-02-MIDAS study (NCT04934475) evaluated a minimal residual disease (MRD)-driven consolidation and maintenance strategy following induction with isatuximab, carfilzomib, lenalidomide, and dexamethasone (IsaKRD) in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM)...MRD-positive patients after induction (MRD ≥10⁻⁵) were randomized to either single ASCT plus 2 cycles of IsaKRD (Arm C) or tandem ASCT (Arm D) followed by isatuximab plus iberdomide maintenance... After 6 induction cycles with IsaKRD, in patients who achieved MRD negativity at 10⁻⁵, MRD negativity rates at 10⁻⁶ before maintenance were not significantly different between the transplant-based approach and IsaKRD consolidation alone, whereas in patients who do not achieve MRD negativity at 10-5, tandem ASCT did not significantly improve MRD negativity rates at 10⁻⁶..."

P3 data • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoD™ Agent, With R-CHOP, As First-line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial (SOHO 2024) - P1 | "The ongoing CC-220-DLBCL-001 trial of GOLCA+R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (NCT04884035) has shown manageable safety and encouraging efficacy in untreated a-BCL. GOLCA+R-CHOP had a high rate of durable CMRs irrespective of cell of origin; promising 12-month progression-free survival, including in HR patients; and a manageable safety profile without compromising curative treatment. This supports the randomized phase 3 GOLSEEK-1 trial of untreated HR LBCL."

Clinical • P1 data • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

GOLSEEK-1: A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY OF GOLCADOMIDE + R-CHOP VERSUS PLACEBO + R-CHOP IN PATIENTS WITH PREVIOUSLY UNTREATED, HIGH-RISK, LARGE B-CELL LYMPHOMA (ICML 2025) - P3 | "Introduction: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is standard treatment (Tx) for diffuse large B-cell lymphoma (DLBCL) and is curative in ≈60–70% of patients (pts)...In the phase 1b study CC-220-DLBCL-001, GOLCA + R-CHOP was well tolerated, with promising activity and combinability and high rates of durable responses irrespective of COO in pts with previously untreated aggressive BCL, including HR pts...Key secondary endpoints include PFS in non–high-grade BCL, event-free survival, independently assessed complete metabolic response, undetectable minimal residual disease by PhasED-Seq, and overall survival. This study is recruiting globally at 309 sites in 36 countries."

Clinical • P3 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • CRBN • IKZF1

GOLCADOMIDE (GOLCA [CC-99282]), A POTENTIAL FIRST-IN-CLASS ORAL CELMOD™ AGENT, PLUS R-CHOP IN PATIENTS (PTS) WITH UNTREATED AGGRESSIVE B-CELL LYMPHOMA (A-BCL): SAFETY AND 12-MONTH EFFICACY RESULTS (EHA 2024) - P1 | "CC-220-DLBCL-001 (NCT04884035) is an ongoing phase 1b,open-label, multicenter, dose escalation/expansion trial to assess safety and preliminary 1L GOLCA+R-CHOPefficacy in a-BCL. GOLCA at DL1 with R-CHOP resulted in a high rate of durable CMRs irrespective of COO and a promising 12-month PFS in the overall and HR populations. GOLCA+R-CHOP demonstrated a manageable safety profile; theaddition of GOLCA to R-CHOP did not compromise curative treatment. These data support the initiation of therandomized phase 3 trial GOLSEEK-1 of GOLCA+R-CHOP versus R-CHOP as 1L treatment in pts with HR DLBCL."

Clinical • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • IKZF1

Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study (ASH 2022) - P1/2 | "In vitro studies suggest IBER enhances T-cell immunostimulatory and direct cytotoxic effects versus lenalidomide...Methods Pts with RR lymphomas and ≥ 2 prior lines of treatment (tx) were given escalating doses of IBER alone (cohort A: all lymphomas), or with rituximab (cohort B: all B-cell lymphomas) or obinutuzumab (cohort C: marginal zone lymphoma [MZL] or grade 1–3a follicular lymphoma [FL]) to determine maximum tolerated dose (MTD)...These data highlight the potential of CELMoD agent-based tx in pts with RR lymphoma to address unmet needs such as treating disease progression after CAR T cell tx. Study support: This study was funded by Bristol Myers Squibb."

Clinical • Combination therapy • Monotherapy • P1/2 data • Anemia • Constipation • Diffuse Large B Cell Lymphoma • Endocrine Disorders • Febrile Neutropenia • Follicular Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Marginal Zone Lymphoma • Metabolic Disorders • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Septic Shock • Targeted Protein Degradation • Thrombocytopenia • CD4 • CRBN • IKZF1

Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL) (ASH 2024) - P1 | "CC-220-DLBCL-001 (NCT04884035) is an ongoing phase 1b, open-label, multicenter, dose-escalation/expansion trial to assess safety and preliminary 1L GOLCA + R-CHOP efficacy in a-BCL. Although pt numbers were small, the data suggest that 0.4 mg is efficacious in high-risk ctDNA and high-genomic risk pts, independent of COO, and support the 0.4 mg GOLCA + R-CHOP regimen in the randomized phase 3 trial GOLSEEK-1. Interim MRD- may play a role in future adaptive trial designs."

Minimal residual disease • Residual disease • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Targeted Protein Degradation • CRBN • IKZF1 • TP53

MINIMAL RESIDUAL DISEASE-DRIVEN STRATEGY FOLLOWING ISATUXIMAB-CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE INDUCTION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PRIMARY ENDPOINTS OF THE PHASE 3 MIDAS TRIAL (EHA 2025) - P3 | "MRD- positive patients after induction (MRD ≥10−5) were randomized to either single ASCT plus 2 cycles of IsaKRD (Arm C) or tandem ASCT (Arm D) followed by isatuximab plus iberdomide maintenance. After 6 induction cycles with IsaKRD, in patients who achieved MRD negativity at 10−5, MRD negativity rates at 10−6 before maintenance were not significantly different between the transplant-based approach and IsaKRD consolidation alone, whereas in patients who do not achieve MRD negativity at 10-5, tandem ASCT did not significantly improve MRD negativity rates at 10−6 before maintenance. Further follow-up, including sustained MRD negativity and PFS data, is needed to evaluate the long-term outcomes of this MRD-adapted strategy."

Minimal residual disease • P3 data • Residual disease • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM (ChiCTR) - P3 | N=1216 | Recruiting | Sponsor: Peking University People's Hospital; Peking University People's Hospital

New P3 trial • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): Updated results from the CC-220-MM-001 trial. (ASCO 2025) - P1/2 | "Funded by Bristol Myers Squibb Clinical Trial Registration Number: NCT02773030 Background: Lenalidomide (LEN), bortezomib (BORT), and dexamethasone (DEX) are recommended for NDMM. With longer follow-up (13–25 mo), IberVd confirmed durable deep responses, with ≥ CR % rising from 56.3% to 75.0%, and an encouraging safety profile with no new signals in pts with TNE NDMM. These data support IberVd evaluation in the frontline setting."

Fatigue • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Novel Coronavirus Disease • Oncology • Pain • Pneumonia • Respiratory Diseases • Thrombocytopenia • Transplantation

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial (ASH 2022) - P1b/2a, P3 | " Eligible pts had RRMM, had received ≥ 3 prior lines of therapy (including lenalidomide or pomalidomide, a PI, an anti-CD38 mAb, and an anti-BCMA therapy) and had documented progressive disease (PD) on or within 60 days of their last antimyeloma therapy (documented PD if chimeric antigen receptor [CAR] T cell therapy was the last therapy). IBER + DEX showed encouraging efficacy and safety in pts with triple-class-exposed RRMM and prior anti-BCMA therapy. The results are comparable to those from Cohort D of the same study, which is assessing IBER + DEX in pts with triple-class refractory RRMM. These findings support further development of IBER in RRMM, including in anti-BCMA-exposed pts."

Combination therapy • Anemia • Cardiovascular • Febrile Neutropenia • Hematological Malignancies • Hypertension • Immune Modulation • Immunology • Infectious Disease • Inflammation • Leukopenia • Multiple Myeloma • Neutropenia • Plasmacytoma • Pneumonia • Respiratory Diseases • Septic Shock • Targeted Protein Degradation • Thrombocytopenia • CD4 • CD8 • CRBN

Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial (IMW 2023) - P1b/2a | "Introduction: In patients (pts) with transplant-ineligible (TNE) NDMM, the immunomodulatory drug (IMiD®) lenalidomide forms a standard of care in combination with bortezomib (BORT) and dexamethasone (DEX). IberVd showed high efficacy with deep, ongoing responses in this cohort of mostly older pts with TNE NDMM. The safety profile was manageable with no new safety signals, and no pts discontinued due to AEs. These data support further assessment of IBER combinations in the frontline setting."

Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Oncology • Pain • Pneumonia • Respiratory Diseases • Targeted Protein Degradation • Transplantation • CRBN

Iberdomide, daratumumab, and dexamethasone (IberDd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): results from the CC-220-MM-001 trial (IMW 2024) - P1/2 | "Introduction: Lenalidomide (LEN), combined with daratumumab (DARA) and dexamethasone (DEX), is a standard of care for patients (pts) with TNE NDMM. In pts with TNE NDMM, preliminary data with IberDd showed high efficacy and a manageable safety profile with no new safety signals. Similar results were observed across dose levels. IberDd is being evaluated in an ongoing phase 3 trial in RRMM, and these data further support the evaluation of IBER in NDMM."

Bone Marrow Transplantation • Diabetes • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Novel Coronavirus Disease • Oncology • Plasmacytoma • Pneumonia • Renal Disease • Respiratory Diseases • Transplantation • CRBN • IKZF1

Efficacy and Safety of Iberdomide, Daratumumab, and Dexamethasone, in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients: Initial Analysis of the GEM-IBERDARAX trial (IMS 2025) - "Introduction: In elderly transplant-ineligible newly diagnosed multiple myeloma (TIE NDMM) patients, daratumumab, lenalidomide, and dexamethasone (DRd) is a standard of care. This initial analysis demonstrates that Iberdaradex is effective in TIE NDMM patients, and it is remarkable that most of this population was frail or ultra frail. The VGPR and CR or better rates of 83.5% and 34.2% are encouraging. The safety profile after 6 cycles was acceptable and manageable in this particularly frail population."

Clinical • Late-breaking abstract • Dermatology • Epilepsy • Fatigue • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation